GlassScriptPhysician profile
Henry Q Xiong
NPI 1518910561
$65,816.14
in general payments reported to CMS, 2019-2025
54 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $4,376 · 2021: $2,304 · 2022: $8,009 · 2023: $9,300 · 2024: $1,624 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,432 · Food and Beverage: $4,169 · Honoraria: $2,500 · Travel and Lodging: $968 · Education: $16.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,842.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,432.00 |
| Food and Beverage | $4,169.32 |
| Honoraria | $2,500.00 |
| Travel and Lodging | $967.79 |
| Education | $16.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $9,669.59 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $8,392.73 | 2022-2025 | Imfinzi, Enhertu, Datroway |
| Bayer Healthcare Pharmaceuticals INC. | $8,017.24 | 2019-2020 | |
| Taiho Oncology, INC. | $6,270.80 | 2019-2023 | |
| Lilly USA, LLC | $4,975.64 | 2020-2025 | Verzenio, Jaypirca |
| Kite Pharma, INC. | $4,779.51 | 2019 | |
| Seagen INC. | $4,428.65 | 2019-2023 | Tukysa |
| Tesaro, INC. | $3,149.72 | 2019 | |
| Exelixis INC. | $2,900.79 | 2019-2025 | Cabometyx |
| Eisai INC. | $2,268.39 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $2,089.01 | 2019-2025 | |
| Beone Medicines USA, INC. | $1,976.16 | 2025 | Tevimbra |
| Array Biopharma INC | $1,940.31 | 2021-2025 | Lorbrena, Mektovi, Braftovi |
| E.R. Squibb & Sons, L.L.C. | $574.54 | 2019-2025 | Opdivo, Reblozyl |
| Daiichi Sankyo INC. | $467.16 | 2019-2025 | Enhertu, Datroway |
Show all 51 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Xiong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.